CBI

Clal Biotechnology Industries – a leading Israeli life sciences investment company

about cbi

Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI). CBI supports life science ventures by identifying and empowering science-backed projects and proactively guiding them to fruition

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

Cactus Acquisition Corp. 1

The Cactus Acquisition Corp. 1 (Nasdaq: CCTSU) is a SPAC focusing on Isareli-related targets in the healthcare business
+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Gamida Cell's lead product, omidubicel, has recently successfully completed a phase III clinical trial in hematological malignancies.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer and infectious diseases.
+

Cadent Therapeutics

Cadent Therapeutics is developing innovative drugs for neurological and psychiatric disorders. This company has been recently acquired by Novartis.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company discovering and developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities.
+

Biokine

Biokine Therapeutics is developing novel therapeutics to treat cancer. It's lead product, motixafortide (formerly BL-8040), is licensed to BiolineRx and is currently in phase III clinical development.

See complete portfolio

Press Releases

2021

07

Nov

Biokine: BioLineRx to Present Additional Motixafortide Phase 3 Data at the 2021 American Society of Hematology Annual Meeting
07

Nov

Gamida Cell: Positive Omidubicel and GDA-201 Data to Be Presented at 2021 ASH Annual Meeting
03

Nov

Cactus Acquisition Corp. 1: Closing of Upsized $126.5 Million IPO, Including Fully-Exercised Over-Allotment Option
01

Nov

Cactus Acquisition Corp. 1: Full Exercise of $16.5M Over-Allotment Option Related to the Initial Public Offering
07

Oct

Elicio Therapeutics: First Patient Dosed in ELI-002’s Trial in KRAS-Driven Cancers
29

Oct

Cactus Acquisition Corp. 1: Launch of a $100M IPO

Read all Press Releases